Ladenburg Thalmann Financial Services
http://www.ladenburg.comLadenburg Thalmann Financial Services, Inc. (AMEX: LTS) provides retail and institutional securities brokerage, investment banking, investment activities, and asset management services as well as equity research. In May of 2008, Ladenburg Thalmann acquired Punk Ziegel & Company to strengthen its trading, research, and investment banking departments. Ladenburg Thalmann is headquartered in Miami, FL.
View Older Stories View More Recent Stories
-
Innovative Industrial Properties Inc. (IIPR) Prices 2.68M Shares at $83.35
-
Innovative Industrial Properties Upsizes and Prices Public Offering of Common Stock
-
Innovative Industrial Properties Inc. (IIPR) Announces Proposed 1.8M Share Common Offering
-
Innovative Industrial Properties Announces Public Offering of 1,800,000 Shares of Common Stock
-
Millendo Therapeutics Inc. (MLND) PT Lowered to $5 at Ladenburg Thalmann
-
UPDATE: Ladenburg Thalmann Upgrades IZEA, Inc (IZEA) to Buy
-
UPDATE: Ladenburg Thalmann Starts Windtree Therapeutics (WINT) at Buy
-
Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
UPDATE: (IIPR) PT Raised to $104 at Ladenburg Thalmann
-
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
-
Athenex (ATNX) Announces $225 Million Loan Agreement with Oaktree
-
Athenex Announces $225 Million Loan Agreement with Oaktree
-
Athenex Announces $225 Million Loan Agreement with Oaktree
-
VICI Properties Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Alpine Immune Sciences (ALPN) PT Raised to 'Street High' $27 at Ladenburg Thalmann
-
Leap Therapeutics (LPTX) Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
-
Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
-
Saratoga Investment Corp. Prices Public Offering of $37.5 Million 7.25% Notes Due 2025
-
Saratoga Investment Corp. Prices Public Offering of $37.5 Million 7.25% Notes Due 2025
-
Saratoga Investment Corp. Announces Offering of Notes Due 2025 and BBB Investment Grade Rating from Egan-Jones Ratings Company
-
Saratoga Investment Corp. Announces Offering of Notes Due 2025 and BBB Investment Grade Rating from Egan-Jones Ratings Company
-
VICI Properties Inc. (VICI) Prices 26M Share Common Offering at $22.15/Sh
-
VICI Properties Inc. Announces Pricing of Public Offering of Common Stock
-
Triumph Bancorp Announces Pricing of Offering of Series C Preferred Stock Depositary Shares
-
Pre-Open Stock Movers 06/16: (IDYA) (IQ) (HEAR) Higher; (IZEA) (CLDX) (CHK) Lower (more...)
-
Triumph Bancorp Announces Proposed Offering of Series C Preferred Stock
-
Ladenburg Thalmann Downgrades IZEA, Inc (IZEA) to Neutral
-
Forte Biosciences, Inc. Announces Closing of Merger With Tocagen
-
Immunic Inc. (IMUX) Prices 2.18M Share Common Stock Offering at $11.40/Each
-
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
-
Delmar Pharma (DMPI) to Acquire Adgero Biopharmaceuticals
-
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
-
GrowGeneration Announces $35,000,000 Follow-On Public Offering
-
Spirit Realty Capital (SRC) Prices 8M Share Common Offering at $37.75/Sh
-
Spirit Realty Capital, Inc. Announces Pricing of Public Offering of 8,000,000 Shares of Common Stock
-
Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering
-
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
-
Cellectar Biosciences (CLRB) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock, Warrants
-
Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering
-
UPDATE: Ladenburg Thalmann Downgrades Novus Therapeutics, Inc (NVUS) to Neutral
-
UPDATE: Ladenburg Thalmann Starts Medical Transcription Billing (MTBC) at Buy
-
Ladenburg Thalmann Downgrades Canopy Growth (WEED:CN) (CGC) to Neutral
-
Novus Therapeutics (NVUS) Phase 2a Trial of OP0201 in Acute Otitis Media Did Not Achieve Statistical Significance for Primary Efficacy Endpoints
-
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
-
Tourmaline Partners Adds Three Senior Executives Amid Continued Growth
-
Scorpio Tankers Inc. Announces Pricing of $25 Million 7.00% Senior Unsecured Notes Due 2025
-
Scorpio Tankers Inc. Announces Public Offering of Senior Unsecured Notes Due 2025
-
Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option
-
Jaguar Health (JAGX) Announces Exercise of Warrants for $4.45 Million Gross Proceeds
-
Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds

